Proprotein Convertase Subtilisin/Kexin Type 9 Market Report

Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size, Status and Forecast 2014-2026

  • POSTDATE：Feb 04, 2020
  • PAGES：159
  • REPORT CODE：GMM460772
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The Proprotein Convertase Subtilisin/Kexin Type 9 market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 5.6% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Segmentations:

    By Player:

    • Ensemble Therapeutics Corp

    • BioLingus AG

    • Betagenon AB

    • The Medicines Company

    • Novartis AG

    • Bioleaders Corp

    • Eli Lilly and Co

    • Kowa Co Ltd

    • Serometrix LLC

    • AFFiRiS AG

    • Pfizer Inc

    • Dicerna Pharmaceuticals Inc

    • Catabasis Pharmaceuticals Inc

    • Regeneron Pharmaceuticals Inc

    • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

    By Type:

    • SX-PCK9

    • O-304

    • K-312

    • BLSM-201

    • DCRPCSK-9

    • Others

    By End-User:

    • Cardiovascular Disease

    • Homozugous Familial Hyperchalesterolemia

    • Liver Disease

    • Metabolic Syndrome

    • Others

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate of SX-PCK9 from 2014 to 2026

    • 1.3.2 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate of O-304 from 2014 to 2026

    • 1.3.3 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate of K-312 from 2014 to 2026

    • 1.3.4 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate of BLSM-201 from 2014 to 2026

    • 1.3.5 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate of DCRPCSK-9 from 2014 to 2026

    • 1.3.6 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate of Others from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate of Cardiovascular Disease from 2014 to 2026

    • 1.4.2 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate of Homozugous Familial Hyperchalesterolemia from 2014 to 2026

    • 1.4.3 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate of Liver Disease from 2014 to 2026

    • 1.4.4 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate of Metabolic Syndrome from 2014 to 2026

    • 1.4.5 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate of Others from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Proprotein Convertase Subtilisin/Kexin Type 9 Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Proprotein Convertase Subtilisin/Kexin Type 9 by Major Types

      • 3.4.1 Market Size and Growth Rate of SX-PCK9

      • 3.4.2 Market Size and Growth Rate of O-304

      • 3.4.3 Market Size and Growth Rate of K-312

      • 3.4.4 Market Size and Growth Rate of BLSM-201

      • 3.4.5 Market Size and Growth Rate of DCRPCSK-9

      • 3.4.6 Market Size and Growth Rate of Others

    4 Segmentation of Proprotein Convertase Subtilisin/Kexin Type 9 Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Proprotein Convertase Subtilisin/Kexin Type 9 by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Proprotein Convertase Subtilisin/Kexin Type 9 for Cardiovascular Disease

      • 4.4.2 Market Size and Growth Rate of Proprotein Convertase Subtilisin/Kexin Type 9 for Homozugous Familial Hyperchalesterolemia

      • 4.4.3 Market Size and Growth Rate of Proprotein Convertase Subtilisin/Kexin Type 9 for Liver Disease

      • 4.4.4 Market Size and Growth Rate of Proprotein Convertase Subtilisin/Kexin Type 9 for Metabolic Syndrome

      • 4.4.5 Market Size and Growth Rate of Proprotein Convertase Subtilisin/Kexin Type 9 for Others

    5 Market Analysis by Major Regions

    • 5.1 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Production Analysis by Top Regions

    • 5.2 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Analysis by Top Regions

    • 5.3 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany Proprotein Convertase Subtilisin/Kexin Type 9 Production, Import, Consumption and Export Analysis

      • 5.3.2 UK Proprotein Convertase Subtilisin/Kexin Type 9 Production, Import, Consumption and Export Analysis

      • 5.3.3 France Proprotein Convertase Subtilisin/Kexin Type 9 Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy Proprotein Convertase Subtilisin/Kexin Type 9 Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain Proprotein Convertase Subtilisin/Kexin Type 9 Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland Proprotein Convertase Subtilisin/Kexin Type 9 Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia Proprotein Convertase Subtilisin/Kexin Type 9 Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland Proprotein Convertase Subtilisin/Kexin Type 9 Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey Proprotein Convertase Subtilisin/Kexin Type 9 Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Proprotein Convertase Subtilisin/Kexin Type 9 Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) Proprotein Convertase Subtilisin/Kexin Type 9 Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) Proprotein Convertase Subtilisin/Kexin Type 9 Production, Import, Consumption and Export Analysis

    6 Product Circulation of Proprotein Convertase Subtilisin/Kexin Type 9 Market among Top Countries

    • 6.1 Top 5 Export Countries in Proprotein Convertase Subtilisin/Kexin Type 9 Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Proprotein Convertase Subtilisin/Kexin Type 9 Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Proprotein Convertase Subtilisin/Kexin Type 9 Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Proprotein Convertase Subtilisin/Kexin Type 9 Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Proprotein Convertase Subtilisin/Kexin Type 9 Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Proprotein Convertase Subtilisin/Kexin Type 9 Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis

    • 7.1 Germany Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis by Major Types

    • 7.2 Germany Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis by Major End-Users

    8. UK Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis

    • 8.1 UK Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis by Major Types

    • 8.2 UK Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis by Major End-Users

    9. France Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis

    • 9.1 France Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis by Major Types

    • 9.2 France Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis by Major End-Users

    10. Italy Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis

    • 10.1 Italy Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis by Major Types

    • 10.2 Italy Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis by Major End-Users

    11. Spain Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis

    • 11.1 Spain Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis by Major Types

    • 11.2 Spain Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis by Major End-Users

    12. Poland Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis

    • 12.1 Poland Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis by Major Types

    • 12.2 Poland Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis by Major End-Users

    13. Russia Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis

    • 13.1 Russia Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis by Major Types

    • 13.2 Russia Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis by Major End-Users

    14. Switzerland Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis

    • 14.1 Switzerland Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis by Major Types

    • 14.2 Switzerland Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis by Major End-Users

    15. Turkey Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis

    • 15.1 Turkey Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis by Major Types

    • 15.2 Turkey Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis by Top Countries

      • 16.3.1 Denmark Proprotein Convertase Subtilisin/Kexin Type 9 Market Volume and Growth Rate

      • 16.3.2 Finland Proprotein Convertase Subtilisin/Kexin Type 9 Market Volume and Growth Rate

      • 16.3.3 Norway Proprotein Convertase Subtilisin/Kexin Type 9 Market Volume and Growth Rate

      • 16.3.4 Sweden Proprotein Convertase Subtilisin/Kexin Type 9 Market Volume and Growth Rate

      • 16.3.6 Iceland Proprotein Convertase Subtilisin/Kexin Type 9 Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis by Top Countries

      • 17.3.1 Belgium Proprotein Convertase Subtilisin/Kexin Type 9 Market Volume and Growth Rate

      • 17.3.2 Netherlands Proprotein Convertase Subtilisin/Kexin Type 9 Market Volume and Growth Rate

      • 17.3.3 Luxembourg Proprotein Convertase Subtilisin/Kexin Type 9 Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) Proprotein Convertase Subtilisin/Kexin Type 9 Landscape Analysis by Top Countries

      • 18.3.1 Estonia Proprotein Convertase Subtilisin/Kexin Type 9 Market Volume and Growth Rate

      • 18.3.2 Latvia Proprotein Convertase Subtilisin/Kexin Type 9 Market Volume and Growth Rate

      • 18.3.3 Lithuania Proprotein Convertase Subtilisin/Kexin Type 9 Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Ensemble Therapeutics Corp

      • 19.1.1 Ensemble Therapeutics Corp Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 BioLingus AG

      • 19.2.1 BioLingus AG Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 Betagenon AB

      • 19.3.1 Betagenon AB Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 The Medicines Company

      • 19.4.1 The Medicines Company Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 Novartis AG

      • 19.5.1 Novartis AG Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 Bioleaders Corp

      • 19.6.1 Bioleaders Corp Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 Eli Lilly and Co

      • 19.7.1 Eli Lilly and Co Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 Kowa Co Ltd

      • 19.8.1 Kowa Co Ltd Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 Serometrix LLC

      • 19.9.1 Serometrix LLC Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    • 19.10 AFFiRiS AG

      • 19.10.1 AFFiRiS AG Company Profile and Development Status

      • 19.10.2 Market Performance

      • 19.10.3 Product and Service Introduction

    • 19.11 Pfizer Inc

      • 19.11.1 Pfizer Inc Company Profile and Development Status

      • 19.11.2 Market Performance

      • 19.11.3 Product and Service Introduction

    • 19.12 Dicerna Pharmaceuticals Inc

      • 19.12.1 Dicerna Pharmaceuticals Inc Company Profile and Development Status

      • 19.12.2 Market Performance

      • 19.12.3 Product and Service Introduction

    • 19.13 Catabasis Pharmaceuticals Inc

      • 19.13.1 Catabasis Pharmaceuticals Inc Company Profile and Development Status

      • 19.13.2 Market Performance

      • 19.13.3 Product and Service Introduction

    • 19.14 Regeneron Pharmaceuticals Inc

      • 19.14.1 Regeneron Pharmaceuticals Inc Company Profile and Development Status

      • 19.14.2 Market Performance

      • 19.14.3 Product and Service Introduction

    • 19.15 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

      • 19.15.1 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Company Profile and Development Status

      • 19.15.2 Market Performance

      • 19.15.3 Product and Service Introduction

    The List of Tables and Figures (Totals 70 Figures and 117 Tables)

    • Figure Product Picture

    • Figure Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate of SX-PCK9 from 2014 to 2026

    • Figure Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate of O-304 from 2014 to 2026

    • Figure Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate of K-312 from 2014 to 2026

    • Figure Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate of BLSM-201 from 2014 to 2026

    • Figure Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate of DCRPCSK-9 from 2014 to 2026

    • Figure Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate of Others from 2014 to 2026

    • Figure Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate of Cardiovascular Disease from 2014 to 2026

    • Figure Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate of Homozugous Familial Hyperchalesterolemia from 2014 to 2026

    • Figure Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate of Liver Disease from 2014 to 2026

    • Figure Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate of Metabolic Syndrome from 2014 to 2026

    • Figure Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate of Others from 2014 to 2026

    • Figure Germany Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

    • Figure UK Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

    • Figure France Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

    • Figure Finland Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

    • Figure Norway Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Proprotein Convertase Subtilisin/Kexin Type 9 Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Proprotein Convertase Subtilisin/Kexin Type 9

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Proprotein Convertase Subtilisin/Kexin Type 9 by Different Types from 2014 to 2026

    • Table Consumption Share of Proprotein Convertase Subtilisin/Kexin Type 9 by Different Types from 2014 to 2026

    • Figure Market Size and Growth Rate of SX-PCK9

    • Figure Market Size and Growth Rate of O-304

    • Figure Market Size and Growth Rate of K-312

    • Figure Market Size and Growth Rate of BLSM-201

    • Figure Market Size and Growth Rate of DCRPCSK-9

    • Figure Market Size and Growth Rate of Others

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Proprotein Convertase Subtilisin/Kexin Type 9 by Different End-Users from 2014 to 2026

    • Table Consumption Share of Proprotein Convertase Subtilisin/Kexin Type 9 by Different End-Users from 2014 to 2026

    • Figure Market Size and Growth Rate of Cardiovascular Disease

    • Figure Market Size and Growth Rate of Homozugous Familial Hyperchalesterolemia

    • Figure Market Size and Growth Rate of Liver Disease

    • Figure Market Size and Growth Rate of Metabolic Syndrome

    • Figure Market Size and Growth Rate of Others

    • Table Europe Proprotein Convertase Subtilisin/Kexin Type 9 Production by Major Regions

    • Table Europe Proprotein Convertase Subtilisin/Kexin Type 9 Production Share by Major Regions

    • Figure Europe Proprotein Convertase Subtilisin/Kexin Type 9 Production Share by Major Countries and Regions in 2014

    • Table Europe Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by Major Regions

    • Table Europe Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Share by Major Regions

    • Table Germany Proprotein Convertase Subtilisin/Kexin Type 9 Production, Import, Consumption and Export Analysis

    • Table UK Proprotein Convertase Subtilisin/Kexin Type 9 Production, Import, Consumption and Export Analysis

    • Table France Proprotein Convertase Subtilisin/Kexin Type 9 Production, Import, Consumption and Export Analysis

    • Table Italy Proprotein Convertase Subtilisin/Kexin Type 9 Production, Import, Consumption and Export Analysis

    • Table Spain Proprotein Convertase Subtilisin/Kexin Type 9 Production, Import, Consumption and Export Analysis

    • Table Poland Proprotein Convertase Subtilisin/Kexin Type 9 Production, Import, Consumption and Export Analysis

    • Table Russia Proprotein Convertase Subtilisin/Kexin Type 9 Production, Import, Consumption and Export Analysis

    • Table Switzerland Proprotein Convertase Subtilisin/Kexin Type 9 Production, Import, Consumption and Export Analysis

    • Table Turkey Proprotein Convertase Subtilisin/Kexin Type 9 Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Proprotein Convertase Subtilisin/Kexin Type 9 Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Proprotein Convertase Subtilisin/Kexin Type 9 Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) Proprotein Convertase Subtilisin/Kexin Type 9 Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Proprotein Convertase Subtilisin/Kexin Type 9 Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Proprotein Convertase Subtilisin/Kexin Type 9 Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Proprotein Convertase Subtilisin/Kexin Type 9 Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Proprotein Convertase Subtilisin/Kexin Type 9 Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by Types from 2014 to 2026

    • Table Germany Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Share by Types from 2014 to 2026

    • Table Germany Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by End-Users from 2014 to 2026

    • Table Germany Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Share by End-Users from 2014 to 2026

    • Table UK Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by Types from 2014 to 2026

    • Table UK Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Share by Types from 2014 to 2026

    • Table UK Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by End-Users from 2014 to 2026

    • Table UK Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Share by End-Users from 2014 to 2026

    • Table France Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by Types from 2014 to 2026

    • Table France Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Share by Types from 2014 to 2026

    • Table France Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by End-Users from 2014 to 2026

    • Table France Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Share by End-Users from 2014 to 2026

    • Table Italy Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by Types from 2014 to 2026

    • Table Italy Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Share by Types from 2014 to 2026

    • Table Italy Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by End-Users from 2014 to 2026

    • Table Italy Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Share by End-Users from 2014 to 2026

    • Table Spain Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by Types from 2014 to 2026

    • Table Spain Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Share by Types from 2014 to 2026

    • Table Spain Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by End-Users from 2014 to 2026

    • Table Spain Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Share by End-Users from 2014 to 2026

    • Table Poland Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by Types from 2014 to 2026

    • Table Poland Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Share by Types from 2014 to 2026

    • Table Poland Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by End-Users from 2014 to 2026

    • Table Poland Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Share by End-Users from 2014 to 2026

    • Table Russia Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by Types from 2014 to 2026

    • Table Russia Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Share by Types from 2014 to 2026

    • Table Russia Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by End-Users from 2014 to 2026

    • Table Russia Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by Types from 2014 to 2026

    • Table Switzerland Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Share by Types from 2014 to 2026

    • Table Switzerland Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by End-Users from 2014 to 2026

    • Table Switzerland Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Share by End-Users from 2014 to 2026

    • Table Turkey Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by Types from 2014 to 2026

    • Table Turkey Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Share by Types from 2014 to 2026

    • Table Turkey Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by End-Users from 2014 to 2026

    • Table Turkey Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark Proprotein Convertase Subtilisin/Kexin Type 9 Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Proprotein Convertase Subtilisin/Kexin Type 9 Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Proprotein Convertase Subtilisin/Kexin Type 9 Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Proprotein Convertase Subtilisin/Kexin Type 9 Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Proprotein Convertase Subtilisin/Kexin Type 9 Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium Proprotein Convertase Subtilisin/Kexin Type 9 Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Proprotein Convertase Subtilisin/Kexin Type 9 Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg Proprotein Convertase Subtilisin/Kexin Type 9 Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Proprotein Convertase Subtilisin/Kexin Type 9 Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Proprotein Convertase Subtilisin/Kexin Type 9 Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia Proprotein Convertase Subtilisin/Kexin Type 9 Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia Proprotein Convertase Subtilisin/Kexin Type 9 Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries Proprotein Convertase Subtilisin/Kexin Type 9 Market Volume and Growth Rate from 2014 to 2026

    • Table Company Profile and Development Status of Ensemble Therapeutics Corp

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Ensemble Therapeutics Corp

    • Figure Sales and Growth Rate Analysis of Ensemble Therapeutics Corp

    • Figure Revenue and Market Share Analysis of Ensemble Therapeutics Corp

    • Table Product and Service Introduction of Ensemble Therapeutics Corp

    • Table Company Profile and Development Status of BioLingus AG

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of BioLingus AG

    • Figure Sales and Growth Rate Analysis of BioLingus AG

    • Figure Revenue and Market Share Analysis of BioLingus AG

    • Table Product and Service Introduction of BioLingus AG

    • Table Company Profile and Development Status of Betagenon AB

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Betagenon AB

    • Figure Sales and Growth Rate Analysis of Betagenon AB

    • Figure Revenue and Market Share Analysis of Betagenon AB

    • Table Product and Service Introduction of Betagenon AB

    • Table Company Profile and Development Status of The Medicines Company

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of The Medicines Company

    • Figure Sales and Growth Rate Analysis of The Medicines Company

    • Figure Revenue and Market Share Analysis of The Medicines Company

    • Table Product and Service Introduction of The Medicines Company

    • Table Company Profile and Development Status of Novartis AG

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novartis AG

    • Figure Sales and Growth Rate Analysis of Novartis AG

    • Figure Revenue and Market Share Analysis of Novartis AG

    • Table Product and Service Introduction of Novartis AG

    • Table Company Profile and Development Status of Bioleaders Corp

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Bioleaders Corp

    • Figure Sales and Growth Rate Analysis of Bioleaders Corp

    • Figure Revenue and Market Share Analysis of Bioleaders Corp

    • Table Product and Service Introduction of Bioleaders Corp

    • Table Company Profile and Development Status of Eli Lilly and Co

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Eli Lilly and Co

    • Figure Sales and Growth Rate Analysis of Eli Lilly and Co

    • Figure Revenue and Market Share Analysis of Eli Lilly and Co

    • Table Product and Service Introduction of Eli Lilly and Co

    • Table Company Profile and Development Status of Kowa Co Ltd

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Kowa Co Ltd

    • Figure Sales and Growth Rate Analysis of Kowa Co Ltd

    • Figure Revenue and Market Share Analysis of Kowa Co Ltd

    • Table Product and Service Introduction of Kowa Co Ltd

    • Table Company Profile and Development Status of Serometrix LLC

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Serometrix LLC

    • Figure Sales and Growth Rate Analysis of Serometrix LLC

    • Figure Revenue and Market Share Analysis of Serometrix LLC

    • Table Product and Service Introduction of Serometrix LLC

    • Table Company Profile and Development Status of AFFiRiS AG

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of AFFiRiS AG

    • Figure Sales and Growth Rate Analysis of AFFiRiS AG

    • Figure Revenue and Market Share Analysis of AFFiRiS AG

    • Table Product and Service Introduction of AFFiRiS AG

    • Table Company Profile and Development Status of Pfizer Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer Inc

    • Figure Sales and Growth Rate Analysis of Pfizer Inc

    • Figure Revenue and Market Share Analysis of Pfizer Inc

    • Table Product and Service Introduction of Pfizer Inc

    • Table Company Profile and Development Status of Dicerna Pharmaceuticals Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Dicerna Pharmaceuticals Inc

    • Figure Sales and Growth Rate Analysis of Dicerna Pharmaceuticals Inc

    • Figure Revenue and Market Share Analysis of Dicerna Pharmaceuticals Inc

    • Table Product and Service Introduction of Dicerna Pharmaceuticals Inc

    • Table Company Profile and Development Status of Catabasis Pharmaceuticals Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Catabasis Pharmaceuticals Inc

    • Figure Sales and Growth Rate Analysis of Catabasis Pharmaceuticals Inc

    • Figure Revenue and Market Share Analysis of Catabasis Pharmaceuticals Inc

    • Table Product and Service Introduction of Catabasis Pharmaceuticals Inc

    • Table Company Profile and Development Status of Regeneron Pharmaceuticals Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Regeneron Pharmaceuticals Inc

    • Figure Sales and Growth Rate Analysis of Regeneron Pharmaceuticals Inc

    • Figure Revenue and Market Share Analysis of Regeneron Pharmaceuticals Inc

    • Table Product and Service Introduction of Regeneron Pharmaceuticals Inc

    • Table Company Profile and Development Status of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

    • Figure Sales and Growth Rate Analysis of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

    • Figure Revenue and Market Share Analysis of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

    • Table Product and Service Introduction of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US